Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Previous Article in Special Issue
A correction was published on 18 December 2012, see Int. J. Mol. Sci. 2012, 13(12), 17290-17291.

Int. J. Mol. Sci. 2012, 13(9), 10828-10862; doi:10.3390/ijms130910828
Review

Vectors for Inhaled Gene Therapy in Lung Cancer. Application for Nano Oncology and Safety of Bio Nanotechnology

1,2,* , 3
, 1
, 1
, 4
, 5
, 6
 and 1
Received: 30 July 2012; in revised form: 21 August 2012 / Accepted: 22 August 2012 / Published: 29 August 2012
(This article belongs to the Special Issue Bioactive Nanoparticles 2012)
View Full-Text   |   Download PDF [841 KB, updated 19 June 2014; original version uploaded 19 June 2014]
Abstract: Novel aerosol therapeutic modalities have been investigated for lung cancer. Inhaled gene therapy has presented safety and effectiveness previously in cystic fibrosis. However, safety concerns have been raised regarding the safety of non-viral vectors for inhaled gene therapy in lung cancer, and therefore small steps have been made towards this multifunctional treatment modality. During the last decade, numerous new nanocomplexes have been created and investigated as a safe gene delivery nano-vehicle. These formulations are multifunctional; they can be used as either local therapy or carrier for an effective inhaled gene therapy for lung cancer. Herein, we present current and future perspectives of nanocomplexes for inhaled gene therapy treatment in lung cancer.
Keywords: lung cancer; inhaled gene therapy; non-viral vectors; nanocomplexes; nanobiotechnology lung cancer; inhaled gene therapy; non-viral vectors; nanocomplexes; nanobiotechnology
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • Correction

    A correction was published on 18 December 2012: http://www.mdpi.com/1422-0067/13/12/17290 (PDF, 129 KB)

    The authors wish to add this correction on their paper published in IJMS [1]. The first author’s name is misspelled and the correct name is Paul Zarogoulidis. In addition, the 6th author’s name is incorrect and should be corrected to Wolfgang Hohenforst-Schmidt. These errors have been amended in an amended version of the manuscript, which is available from the International Journal of Molecular Sciences website. The authors and publisher apologize for the inconvenience.

Export to BibTeX |
EndNote


MDPI and ACS Style

Zarogouldis, P.; Karamanos, N.K.; Porpodis, K.; Domvri, K.; Huang, H.; Hohenforst-Schimdt, W.; Goldberg, E.P.; Zarogoulidis, K. Vectors for Inhaled Gene Therapy in Lung Cancer. Application for Nano Oncology and Safety of Bio Nanotechnology. Int. J. Mol. Sci. 2012, 13, 10828-10862.

AMA Style

Zarogouldis P, Karamanos NK, Porpodis K, Domvri K, Huang H, Hohenforst-Schimdt W, Goldberg EP, Zarogoulidis K. Vectors for Inhaled Gene Therapy in Lung Cancer. Application for Nano Oncology and Safety of Bio Nanotechnology. International Journal of Molecular Sciences. 2012; 13(9):10828-10862.

Chicago/Turabian Style

Zarogouldis, Paul; Karamanos, Nikos K.; Porpodis, Konstantinos; Domvri, Kalliopi; Huang, Haidong; Hohenforst-Schimdt, Wolfgang; Goldberg, Eugene P.; Zarogoulidis, Konstantinos. 2012. "Vectors for Inhaled Gene Therapy in Lung Cancer. Application for Nano Oncology and Safety of Bio Nanotechnology." Int. J. Mol. Sci. 13, no. 9: 10828-10862.


Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert